The benefits of cardiac resynchronisation therapy (CRT) in selected cohorts with systolic dysfunction and congestive heart failure are well established \[[@CR1]--[@CR3]\]. CRT reduces heart failure hospitalisations, decreases mortality, and improves the quality of life and cardiac function, described as left ventricular (LV) reverse remodelling. CRT improves inter-, intra- and atrio-ventricular dyssynchrony. It is important to stress that there is only a moderate correlation between clinical and echocardiographic response; i.e. patients with improvement in their clinical status might not always show significant reverse remodelling. Nevertheless, the number of patients who do not respond to this therapy remain as high as 30 % to 40 %. The reasons for not responding to CRT are probably complex and multifactorial. Patient selection, accurate assessment of dyssynchrony, LV lead placement and optimal position and device programming are of importance. This necessitates a comprehensive evaluation of baseline and post-implant clinical, electrocardiographic and echocardiographic data. Moreover, LV lead position optimisation and device interrogation are useful for optimising CRT and should be considered to maximise the therapeutic response to CRT. It is recommended to perform AV-delay optimisation in all patients, guided either by the device or by echocardiography. However, the role of AV and VV optimisation regarding long-term outcome remain debatable. The SMART AV trial \[[@CR4]\] showed that patients with normal AV delay did not derive benefit from echo-guided or device-guided AV optimisation compared with the empiric settings. However, patients with prolonged AV conduction were not included in this prospective, randomised trial. Moreover, in the Freedom trial \[[@CR5]\] the authors concluded that routine AV and VV optimisation, by echo or the QuickOpt algorithm in unselected CRT recipients, did not appear to contribute significantly to further improving responsiveness to CRT. A variety of techniques, including echocardiography-guided methods, have been described to determine the optimal AV and VV delays. Many of these techniques have poor reproducibility and are time-consuming \[[@CR6], [@CR7]\]. None of these techniques have been shown to be superior and long-term benefits are lacking. Most device-based algorithms allow a rapid, simplified approach to CRT optimisation. However, their clinical value has also been called into question. Only the CLEAR study \[[@CR8], [@CR9]\] results suggest the clinical value of frequent CRT optimisation by SonR^TM^ algorithm or echocardiography in severe chronic heart failure patients in the long-term.

Recently a new non-invasive finger plethysmographic (Nexfin) method has been used for AV optimisation \[[@CR10]\]. The Nexfin device, which allows measurement of beat-to-beat stroke volume (SV), was validated against echocardiography and the Riva-Rocci/Korotkoff method \[[@CR11], [@CR12]\] and AV optimisation by this device led to an almost 7 % increase in SV \[[@CR10]\].

In this issue of the Journal, Molenaar et al.\[[@CR13]\] present their data on optimisation of CRT in clinical practice during exercise using the Nexfin device. They found a heterogeneous optimal AV delay in their small-sized study population. Currently, optimisation of pacing settings is mainly performed during resting conditions \[[@CR14]\].

A few questions can be asked. The first question is whether the optimal AV delay changes during exercise in heart failure patients? Bogaard et al. \[[@CR14]\] reviewed the literature and found seven small-sized studies which addressed this issue. The reported results were not consistent: a shortening, lengthening or no change in optimal AV delay during exercise was observed. Based on the physiological properties of the AV node in healthy subjects, these heterogeneous responses to exercise were unexpected \[[@CR14]\]. The optimal physiological response to exercise in heart failure patients is probably different compared with healthy subjects. Thus, the findings of Molenaar et al. on the true heterogeneous effect of AV optimisation in heart failure patients are in line with previous reports \[[@CR14]\].

The second question is whether the programming of a rate-adaptive AV delay has a significant influence on outcome. In the same review by Bogaard et al. \[[@CR14]\] it was concluded that in all the studies only acute haemodynamic outcomes were assessed. Molenaar et al. showed an increase of 10 % in stroke volume. This is again an acute haemodynamic measurement. An interesting and relevant question is whether this adaptive AV delay, which is a time-consuming method, has an influence on functional NYHA class and exercise capacity in heart failure patients. Therefore, the long-term follow-up results of their study will be very interesting.

Finally, Molenaar et al. used a non-invasive method provided by the Nexfin device, which is relatively new and is not yet well validated for this purpose. Other methods such as echocardiography, including transmitral flow and LV outflow tract velocity (LVOT-VTI) measurements, have been used much more in clinical practice \[[@CR6], [@CR7]\]. Nevertheless, these methods are time-consuming and are moderately reproducible. Device-based algorithms such as QuickOpt and Smart AV did not show any benefit compared with nominal settings and were not tested during exercise. At the moment, programming a sensed AV delay of 100--120 ms still seems the best practice in the majority of patients until more data on clinical outcome become available \[[@CR4], [@CR10], [@CR14]\]. Currently, two multicentre and randomised trials (Bio-Detect HF and Respond CRT) are investigating the benefits of optimising AV and VV delay on clinical outcome by device-based automated algorithm.

In summary, the 10 % increase in stroke volume due to AV-delay optimisation by the Nexfin device during exercise, which Molenaar et al. have showed, is a very interesting and encouraging result. However, the current methods of optimising rate-adaptive AV delay, including the Nexfin method, need to be tested in a larger number of patients with a longer follow-up before definite conclusions can be made.
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